



# Adjunct Principal Investigator Positions at LBI-RUD and CeMM, Vienna

Starting or consolidated level to begin in 2018/2019

- + Do you want to power-up your medically-oriented research with cutting-edge technologies?
- + Do you want to obtain, secure, navigate and interpret big high-dimensional data to drive network medicine?
- + Do you want to become a successful innovator and translate your findings to impact medical practice?
- + Do you want to join an international group of highly collaborative and supportive colleagues that help you achieve your goals?

There is the opportunity to join the combined faculty of LBI-RUD and CeMM on the MedUni/AKH campus in Vienna at the verge of a new precision medicine era. The era is empowered by a strong partnership of the Medical University of Vienna with CeMM and LBI-RUD and the St. Anna Children's Hospital, and envisages new buildings, new PhD programs, a new boldness in the discovery of therapeutics as well as new alliances for genome-based and image-based diagnostic innovation. Together, this should enable an entire community to tackle the challenges of modern medicine.

If you have the necessary drive and passion to make a difference, apply now for a position of **Adjunct Principal Investigator** at the LBI-RUD/CeMM.



Ludwig Boltzmann Institute  
Rare and Undiagnosed Diseases

Ce-M-M-

Research Center for Molecular Medicine  
of the Austrian Academy of Sciences



## The institutes

CeMM and LBI-RUD have identical principles of excellence, competitiveness, internationality as well as mentoring and training, and both operate in a unique mode of super-cooperation, connecting biology with medicine, experiments with computation, discovery with translation, and science with society. We are partner institutes and located in the very same research building in the middle of the Vienna medical campus. Both have a partnership with the Medical University of Vienna and several faculty members have dual affiliations.

## The research area

To complement and strengthen the current Faculty, CeMM and LBI-RUD are offering Adjunct Principal Investigator positions to highly professional individuals who work on an exciting problem of molecular medicine, preferably but not exclusively pertaining to Rare and Undiagnosed Diseases, Molecular Pharmacology, Immunity, Infection Biology, Inflammation, Neurologic Diseases, Hematopoiesis, Hematological Malignancies, Genome Integrity, Blood, Vascular Disorders or Metabolic Disorders.

## Whom we are looking for

We are looking for MD and/or PhD scientists either at their first independent appointment or already at the consolidation stage to apply their expertise close to a clinical setting in a stimulating research environment. Required are scientific quality and originality, a track record of achievements as well as a collaborative and interdisciplinary mindset.

---

CeMM and LBI-RUD are equal opportunity employers, and the institutes have a strong intellectual environment that stems from the international nature of its employees. We believe that diversity and different cultural backgrounds are a clear advantage to successful research, collaborations, and the day-to-day business.

For more information about CeMM and LBI-RUD, the CeMM PhD Program, and news about our projects and the research environment, please visit the websites: [www.cemm.oeaw.ac.at](http://www.cemm.oeaw.ac.at) and <http://rud.lbg.ac.at/en>



Ludwig Boltzmann Institute  
Rare and Undiagnosed Diseases

Ce-M-M-

Research Center for Molecular Medicine  
of the Austrian Academy of Sciences



## You are

- + a scientist with an own laboratory/ working space, interested in a dual affiliation and research collaboration with CeMM/LBI-RUD
- + full of ideas to translate the opportunities of the genomic age into better therapeutics and diagnostics
- + a person who enjoys teamwork across disciplines and within a broader cultural and social context
- + fully committed to participate in the international CeMM PhD Program (from the common selection of students to teaching activities and the supervision of a student)
- + fully committed to actively participate in regular Faculty meetings, bi-weekly brainstorming (“tea time”) and our weekly scientific Friday Seminars
- + fully committed to join thematic rare disease boards and other activities to bridge fundamental research with clinical impact

## We offer

- + an initial 5-years collaboration/affiliation contract with mid-term review by our CeMM/LBI-RUD Scientific Advisory Board(s); option for extension
- + the unique opportunity to become part of the CeMM/LBI-RUD Faculty. Benefit from lively scientific exchange, extend your network, collaborate and explore new possibilities – in science and beyond.
- + 1 PhD student on a CeMM/LBI-RUD fully paid and on an employment contract and on a relevant collaborative topic, the ability to enroll additional new students through the program with own funding
- + an additional budget of € 12.000/year for consumables and travel expenses
- + vouchers of € 5.000/year for CeMM/ LBI-RUD facility services (sequencing, proteomics, metabolomics, chemical screening, animal research, etc.)
- + access to top administrative and scientific support (grant service, purchasing, HR, PR, cafeteria, etc.)

---

### Application Details

Applications should be written in English and contain

- + Curriculum Vitae with full publication list (and ORCID number)
- + list of up to five most important papers with a short comment on why and what your contribution has been (each max 80 words)
- + funding track record or funding plans
- + names and addresses of three references,
- + short summary of research interests and objectives in particular as how you could profit from the CeMM/LBI-RUD environment (max. 3 pages)

Please send your application files to Ms. Anita Ender, Administrative Director CeMM and Chair of the LBI-RUD Board: [application@cemm.at](mailto:application@cemm.at) and [office@rud.lbg.ac.at](mailto:office@rud.lbg.ac.at)

~~Application deadline: July 31, 2018~~

**New Application Deadline: August 20, 2018**



Ludwig Boltzmann Institute  
Rare and Undiagnosed Diseases

Ce-M-M-

Research Center for Molecular Medicine  
of the Austrian Academy of Sciences



The research focus of **LBI-RUD, the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases** is on rare diseases of the immune system, hematopoiesis, and the nervous system, which all together account for more than 50% of all rare diseases. LBI-RUD research will not only be relevant to the affected individuals and will provide the basis for targeted therapies, but will also provide unique and novel insights into human biology far beyond the specific disease, which will add to our understanding of much more frequent diseases. LBI-RUD is highly connected in global networks to promote cooperation and synergy between different disciplines and to engage rare disease patients, and LBI-RUD also holds close ties with its partner institutions, CeMM, the Medical University of Vienna, and the Children's Cancer Research Institute (CCRI) of the St. Anna Children's Hospital. Kaan Boztug is Director of LBI-RUD since 2016.

The mission of **CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences** is to achieve maximum scientific innovation in molecular medicine to improve healthcare. At CeMM, an international and creative team of scientists and medical doctors pursues free-minded basic life science research in a large and vibrant hospital environment of outstanding medical tradition and practice. CeMM's research is based on post-genomic technologies and focuses on societally important diseases, such as immune disorders and infections, cancer and metabolic disorders. The goal of CeMM is to pioneer the science that nurtures the precise, personalized, predictive and preventive medicine of the future. CeMM is part of EU-LIFE an alliance of 13 top research centers in life sciences to support and strengthen European research excellence. Giulio Superti-Furga is Scientific Director of CeMM since 2005.

---

#### Selected Publications

- + Klampfl et al, NEJM (doi: 10.1056/NEJMoa1615887)
- + Dobbs, Dominguez Conde, Zhang, Parolini et al., NEJM (doi: 10.1056/NEJMoa1413462)
- + Salzer et al, Nat Immunol (doi: 10.1038/ni.3575)
- + Rebsamen et al., Nature (doi: 10.1038/nature14107)
- + Köberlin, Snijder et al., Cell (doi: 10.1016/j.cell.2015.05.051)
- + Li et al., Cell (doi: 10.1016/j.cell.2016.11.010)
- + Ozen, Comrie, Ardy et al., NEJM (doi: 10.1056/NEJMoa1615887)
- + Mazouzi et al., Mol. Cell (doi: 10.1016/j.molcel.2017.10.021)
- + Snijder, Vladimer et al., Lancet Haematol (doi: 10.1016/S2352-3026(17)30208-9)

